Comparative Pharmacology
Head-to-head clinical analysis: NORLESTRIN 28 1 50 versus OGESTREL 0 5 50 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLESTRIN 28 1 50 versus OGESTREL 0 5 50 28.
NORLESTRIN 28 1/50 vs OGESTREL 0.5/50-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial development.
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
One tablet (norgestrel 0.5 mg/ethinyl estradiol 50 mcg) orally once daily for 28-day cycle.
None Documented
None Documented
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Norgestrel: ~45 hours (range 24-56 h) enabling once-daily dosing; Ethinyl estradiol: ~17 hours (range 10-27 h).
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norgestrel and ethinyl estradiol); Fecal: 30-40% via biliary elimination; Unchanged drug: <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive